Cargando…

Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation

Detalles Bibliográficos
Autores principales:	Bulinski, Catherine, Discher, Thomas, Rutsatz, Wiebke, Assmus, Birgit, Krämer, Heidrun H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217831/ https://www.ncbi.nlm.nih.gov/pubmed/35124750 http://dx.doi.org/10.1007/s00415-022-10978-3

Ejemplares similares

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
por: Niemietz, Christoph, et al.
Publicado: (2015)

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
por: Waddington Cruz, Márcia, et al.
Publicado: (2015)

Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant
por: Puffer, Ross C., et al.
Publicado: (2019)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis
por: Kapoor, Mahima, et al.
Publicado: (2019)

Population diversity of the genetically determined TTR expression in human tissues and its implications in TTR amyloidosis
por: Iorio, Andrea, et al.
Publicado: (2017)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021)

Non-invasive risk stratification of patients with TTR amyloidosis
por: Scherer, Katrin A, et al.
Publicado: (2013)

The phenotypical expression of an European inherited TTR amyloidosis in Brazil
por: Cruz, Márcia Waddington, et al.
Publicado: (2015)

TTR amyloidosis: a scientific journey since Andrade
por: Saraiva, Maria João
Publicado: (2015)

Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis
por: Obici, Laura, et al.
Publicado: (2019)

Neuropathology of central nervous system involvement in TTR amyloidosis
por: Taipa, Ricardo, et al.
Publicado: (2022)

TTR Amyloidosis: Current State of Affairs and Promise for the Future
por: Brailovsky, Yevgeniy, et al.
Publicado: (2023)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

SOM0226, a repositioned compound for the treatment of TTR amyloidosis
por: Reig, Núria, et al.
Publicado: (2015)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis
por: Bentellis, Imad, et al.
Publicado: (2019)

Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022)

Four-Chamber Intracardiac Thrombi Complicating Wild-Type TTR Amyloidosis
por: Griffin, Jan M., et al.
Publicado: (2018)

TTR Gly83Arg Mutation: Beyond Familial Vitreous Amyloidosis
por: Li, Zhenxian, et al.
Publicado: (2022)

Cardiac Amyloidosis: A Rare TTR Mutation Found in an Asian Female
por: Mouksian, Kristina, et al.
Publicado: (2023)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia
por: Ziskin, Jennifer L., et al.
Publicado: (2015)

Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases
por: González-Duarte, Alejandra, et al.
Publicado: (2018)

The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis
por: Bemporad, Francesco, et al.
Publicado: (2022)

First Follow-Up of Cardiac Amyloidosis Treated by Tafamidis, Evaluated by Absolute Quantification in Bone Scintigraphy
por: Bellevre, Dimitri, et al.
Publicado: (2021)

Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment
por: Wu, Yuan‐Kun (Aden), et al.
Publicado: (2022)

TTR-FAP: liver transplant vs oral medication. How and when
por: Coelho, Teresa
Publicado: (2015)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2019)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis
por: Nakamura, Makiko, et al.
Publicado: (2023)

Uptake of Aggregating Transthyretin by Fat Body in a Drosophila Model for TTR-Associated Amyloidosis
por: Pokrzywa, Malgorzata, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_98m3rad1853nv0bmgoij7hi1en